Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1H-indazole-3-carbaldehyde is a chemical compound characterized by the molecular formula C9H7N2O. It is a yellow liquid with a melting point of 145-147 °C and a boiling point of 292 °C. 1H-indazole-3-carbaldehyde is recognized for its role as a reactant in the synthesis of pharmaceuticals and organic compounds, as well as a building block in the preparation of various heterocyclic compounds. Its potential pharmacological properties, including anti-cancer activity, and its use as a fluorescent probe for detecting reactive oxygen species, highlight its significance in organic chemistry and pharmaceutical research.

5235-10-9 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 5235-10-9 Structure
  • Basic information

    1. Product Name: 1H-INDAZOLE-3-CARBALDEHYDE
    2. Synonyms: 1H-INDAZOLE-3-CARBALDEHYDE;1H-INDAZOLE-3-CARBOXALDEHYDE;1H-INDAZOLE-3-CARBOXYALDEHYDE;3-INDAZOLECARBALDEHYDE;INDAZOLE-3-CARBOXYALDEHYDE;Indazole-3-carboxaldehyde;3-Formylindazole;3-Formyl-1H-indazole
    3. CAS NO:5235-10-9
    4. Molecular Formula: C8H6N2O
    5. Molecular Weight: 146.15
    6. EINECS: 1312995-182-4
    7. Product Categories: pharmacetical
    8. Mol File: 5235-10-9.mol
  • Chemical Properties

    1. Melting Point: 131-132 °C(Solv: benzene (71-43-2); ligroine (8032-32-4))
    2. Boiling Point: 193.6 °C at 760 mmHg
    3. Flash Point: 71.5 °C
    4. Appearance: /
    5. Density: 1.368 g/cm3
    6. Vapor Pressure: 0.461mmHg at 25°C
    7. Refractive Index: 1.747
    8. Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
    9. Solubility: N/A
    10. PKA: 12.04±0.40(Predicted)
    11. CAS DataBase Reference: 1H-INDAZOLE-3-CARBALDEHYDE(CAS DataBase Reference)
    12. NIST Chemistry Reference: 1H-INDAZOLE-3-CARBALDEHYDE(5235-10-9)
    13. EPA Substance Registry System: 1H-INDAZOLE-3-CARBALDEHYDE(5235-10-9)
  • Safety Data

    1. Hazard Codes: Xn
    2. Statements: 36/37/38-22
    3. Safety Statements: 26-36/37/39
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 5235-10-9(Hazardous Substances Data)

5235-10-9 Usage

Uses

Used in Pharmaceutical Synthesis:
1H-indazole-3-carbaldehyde is used as a reactant for the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its chemical properties make it a versatile component in the creation of diverse organic compounds.
Used in Organic Compounds Preparation:
As a building block, 1H-indazole-3-carbaldehyde is utilized in the preparation of various heterocyclic compounds, which are essential in the field of organic chemistry for their wide range of applications and unique properties.
Used in Anticancer Research:
1H-indazole-3-carbaldehyde is investigated as a potential anti-cancer agent, with studies exploring its effects on cancer cells and its potential to contribute to cancer treatment strategies.
Used in Fluorescent Probe Development:
1H-indazole-3-carbaldehyde is also studied for its potential use as a fluorescent probe for detecting reactive oxygen species, which is crucial for understanding oxidative stress and related biological processes in various research and diagnostic applications.

Check Digit Verification of cas no

The CAS Registry Mumber 5235-10-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,2,3 and 5 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 5235-10:
(6*5)+(5*2)+(4*3)+(3*5)+(2*1)+(1*0)=69
69 % 10 = 9
So 5235-10-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H6N2O/c11-5-8-6-3-1-2-4-7(6)9-10-8/h1-5H,(H,9,10)

5235-10-9 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (734829)  1H-Indazole-3-carboxaldehyde  97%

  • 5235-10-9

  • 734829-500MG

  • 961.74CNY

  • Detail

5235-10-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 1H-Indazole-3-carboxaldehyde

1.2 Other means of identification

Product number -
Other names 1H-indazole-3-carbaldehyde

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:5235-10-9 SDS

5235-10-9Relevant articles and documents

Discovery of Novel Indazoles as Potent and Selective PI3Kδ Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma

Cui, Sunliang,He, Qiaojun,Lou, Shengying,Qi, Jifeng,Tang, Yongmei,Wang, Jiaer,Wang, Weihua,Yang, Bo,Yuan, Tao,Zhu, Hong

, p. 3849 - 3865 (2022/03/14)

PI3Kδ inhibitors have been developed for treatment of B-cell malignancies and inflammatory and autoimmune diseases. However, their therapeutic role in solid tumors like hepatocellular carcinoma (HCC) is rarely reported. Thus, the development of potent and selective PI3Kδ inhibitors with a new chemotype and therapy is highly desirable. Through the scaffold-hopping strategy, indazole was first described as the core structure of propeller-shaped PI3Kδ inhibitors. A total of 26 indazole derivatives were designed and prepared to identify a novel compound 9x with good isoform selectivity, PK profile, and potency. Compared to Idelalisib and Sorafenib, the pharmacodynamic (PD) studies showed that 9x exhibits superior efficacy in HCC cell lines and xenograft models, and the mechanistic study showed that 9x robustly suppresses the downstream AKT pathway to induce subsequent apoptotic cell death in HCC models. Therefore, this work provides a new structural design of PI3Kδ inhibitors for a novel and efficient therapeutic small molecule toward HCC.

Regioselective N-alkylation of the 1H-indazole scaffold; ring substituent and N-alkylating reagent effects on regioisomeric distribution

Alam, Ryan M.,Keating, John J.

supporting information, p. 1939 - 1951 (2021/08/23)

The indazole scaffold represents a promising pharmacophore, commonly incorporated in a variety of therapeutic drugs. Although indazole-containing drugs are frequently marketed as the corresponding N-alkyl 1H- or 2H-indazole derivative, the efficient synthesis and isolation of the desired N-1 or N-2 alkylindazole regioisomer can often be challenging and adversely affect product yield. Thus, as part of a broader study focusing on the synthesis of bioactive indazole derivatives, we aimed to develop a regioselective protocol for the synthesis of N-1 alkylindazoles. Initial screening of various conditions revealed that the combination of sodium hydride (NaH) in tetrahydrofuran (THF) (in the presence of an alkyl bromide), represented a promising system for N-1 selective indazole alkylation. For example, among fourteen C-3 substituted indazoles examined, we observed > 99% N-1 regioselectivity for 3-carboxymethyl, 3-tert-butyl, 3-COMe, and 3-carboxamide indazoles. Further extension of this optimized (NaH in THF) protocol to various C-3, -4, -5, -6, and -7 substituted indazoles has highlighted the impact of steric and electronic effects on N-1/N-2 regioisomeric distribution. For example, employing C-7 NO2 or CO2Me substituted indazoles conferred excellent N-2 regioselectivity (≥ 96%). Importantly, we show that this optimized N-alkylation procedure tolerates a wide structural variety of alkylating reagents, including primary alkyl halide and secondary alkyl tosylate electrophiles, while maintaining a high degree of N-1 regioselectivity.

Biocatalytic reduction of α,β-unsaturated carboxylic acids to allylic alcohols

Aleku, Godwin A.,Leys, David,Roberts, George W.

, p. 3927 - 3939 (2020/07/09)

We have developed robust in vivo and in vitro biocatalytic systems that enable reduction of α,β-unsaturated carboxylic acids to allylic alcohols and their saturated analogues. These compounds are prevalent scaffolds in many industrial chemicals and pharmaceuticals. A substrate profiling study of a carboxylic acid reductase (CAR) investigating unexplored substrate space, such as benzo-fused (hetero)aromatic carboxylic acids and α,β-unsaturated carboxylic acids, revealed broad substrate tolerance and provided information on the reactivity patterns of these substrates. E. coli cells expressing a heterologous CAR were employed as a multi-step hydrogenation catalyst to convert a variety of α,β-unsaturated carboxylic acids to the corresponding saturated primary alcohols, affording up to >99percent conversion. This was supported by the broad substrate scope of E. coli endogenous alcohol dehydrogenase (ADH), as well as the unexpected CC bond reducing activity of E. coli cells. In addition, a broad range of benzofused (hetero)aromatic carboxylic acids were converted to the corresponding primary alcohols by the recombinant E. coli cells. An alternative one-pot in vitro two-enzyme system, consisting of CAR and glucose dehydrogenase (GDH), demonstrates promiscuous carbonyl reductase activity of GDH towards a wide range of unsaturated aldehydes. Hence, coupling CAR with a GDH-driven NADP(H) recycling system provides access to a variety of (hetero)aromatic primary alcohols and allylic alcohols from the parent carboxylates, in up to >99percent conversion. To demonstrate the applicability of these systems in preparative synthesis, we performed 100 mg scale biotransformations for the preparation of indole-3-aldehyde and 3-(naphthalen-1-yl)propan-1-ol using the whole-cell system, and cinnamyl alcohol using the in vitro system, affording up to 85percent isolated yield.

An optimized procedure for direct access to 1: H -indazole-3-carboxaldehyde derivatives by nitrosation of indoles

Chevalier, Arnaud,Ouahrouch, Abdelaaziz,Arnaud, Alexandre,Gallavardin, Thibault,Franck, Xavier

, p. 13121 - 13128 (2018/04/23)

Indazole derivatives are currently drawing more and more attention in medicinal chemistry as kinase inhibitors. 1H-indazole-3-carboxaldehydes are key intermediates to access to a variety of polyfunctionalized 3-substituted indazoles. We report here a general access to this motif, based on the nitrosation of indoles in a slightly acidic environment. These very mild conditions allow the conversion of both electron-rich and electron-deficient indoles into 1H-indazole-3-carboxaldehydes.

Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131)

See, Cheng Shang,Kitagawa, Mayumi,Liao, Pei-Ju,Lee, Kyung Hee,Wong, Jasmine,Lee, Sang Hyun,Dymock, Brian W.

, p. 344 - 367 (2018/07/25)

Selective targeting of cancer cells over normal cells is a key objective of targeted therapy. However few approaches achieve true mechanistic selectivity resulting in debilitating side effects and dose limitation. In this work we describe the discovery of A131 (4a), a new agent with an unprecedented dual mechanism of action targeting both mitosis and autophagy. Compound 4a was first identified in a phenotypic screen in which HeLa cells treated with 4a manifested mitotic arrest along with formation of multiple vesicles. Further investigations showed that 4a causes an increase in mitotic marker pH3 and autophagy marker LC3. Importantly 4a induces cell death in cancer cells while sparing normal cells which regrow after 4a is removed. Dual activities against pH3 and LC3 markers are required for cancer cell selectivity. An extensive SAR investigation confirmed 4a as the optimal dual inhibitor with potency against a panel of 30 cancer cell lines (average antiproliferative GI50 1.5 μM). In a mouse model of paclitaxel-resistant colon cancer, 4a showed 74% tumor growth inhibition when administered at a dose of 20 mg/kg IP twice a day.

SELECTIVE ANTI-CANCER COMPOUNDS

-

Page/Page column 113-114, (2017/01/31)

A compound of formula I, wherein the compound of formula I has the structure: wherein R1 to R5, Y, L, Z and X1 to X7 have meanings given in the description, said compounds having utility in the treatment of hyperproliferative disease.

Design and synthesis of a new indazole library: direct conversion of?N-methoxy-N-methylamides (Weinreb amides) to 3-keto and 3-formylindazoles

Crestey, Fran?ois,Stiebing, Silvia,Legay, Rémi,Collot, Valérie,Rault, Sylvain

, p. 419 - 428 (2007/10/03)

Nucleophilic addition of Grignard or lithiated reagents on the new Weinreb amides 3 and 4 afforded efficiently the corresponding ketones and allowed the design and synthesis of a new indazole library. These 3-ketoindazoles were obtained by a direct and or

New practical access to 2-azatryptophans and dehydro derivatives via the Wittig-Horner reaction

Crestey, Fran?ois,Collot, Valérie,Stiebing, Silvia,Lohier, Jean-Fran?ois,Santos, Jana Sopkova-de Oliveira,Rault, Sylvain

, p. 2457 - 2460 (2007/10/03)

The Wittig-Horner reaction of protected 3-formylindazoles 1 with (±)-N-(benzyloxycarbonyl)-α-phosphonoglycine trimethyl ester 2 has been developed as a new practical synthesis of dehydro 2-azatryptophans and amino acid derivatives. The preparation of 5-br

Tricyclic heterocycles

-

Page/Page column 28, (2008/06/13)

The present invention relates to the compounds of formula I their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing suc

PPAR ACTIVE COMPOUNDS

-

Page 100-101, (2008/06/13)

Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 5235-10-9